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Abstract
Background: This report presents a systematic review of scientific literature published between 1990–2010 relating to the
frequency of human brucellosis, commissioned by WHO. The objectives were to identify high quality disease incidence data
to complement existing knowledge of the global disease burden and, ultimately, to contribute towards the calculation of a
Disability-Adjusted Life Years (DALY) estimate for brucellosis.
Methods/Principal Findings: Thirty three databases were searched, identifying 2,385 articles relating to human brucellosis.
Based on strict screening criteria, 60 studies were selected for quality assessment, of which only 29 were of sufficient quality
for data analysis. Data were only available from 15 countries in the regions of Northern Africa and Middle East, Western
Europe, Central and South America, Sub-Saharan Africa, and Central Asia. Half of the studies presented incidence data, six of
which were longitudinal prospective studies, and half presented seroprevalence data which were converted to incidence
rates. Brucellosis incidence varied widely between, and within, countries. Although study biases cannot be ruled out,
demographic, occupational, and socioeconomic factors likely play a role. Aggregated data at national or regional levels do
not capture these complexities of disease dynamics and, consequently, at-risk populations or areas may be overlooked. In
many brucellosis-endemic countries, health systems are weak and passively-acquired official data underestimate the true
disease burden.
Conclusions: High quality research is essential for an accurate assessment of disease burden, particularly in Eastern Europe,
the Asia-Pacific, Central and South America and Africa where data are lacking. Providing formal epidemiological and
statistical training to researchers is essential for improving study quality. An integrated approach to disease surveillance
involving both human health and veterinary services would allow a better understanding of disease dynamics at the animal-
human interface, as well as a more cost-effective utilisation of resources.
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Introduction
Brucellosis is one of the most common zoonotic infections
globally [1], transmitted to humans through consumption of
unpasteurised dairy products or through direct contact with
infected animals, placentas or aborted foetuses. This bacterial
disease causes a severely debilitating and disabling illness, with
fever, sweating, fatigue, weight loss, headache, and joint pain
persisting for weeks to months. Neurological complications,
endocarditis and testicular or bone abscess formation can also
occur [2]. Additionally, brucellosis has major economic ramifica-
tions due to time lost by patients from normal daily activities [2]
and losses in animal production [3]. In a review of 76 diseases and
syndromes of animals, brucellosis lies within the top 10 in terms of
impact on impoverished people [4].
In 1992, the World Bank commissioned the original Global
Burden of Disease (GBD) study, providing a comprehensive
assessment of 107 diseases and injuries and 10 risk factors in eight
major regions [5]. This review did not include any neglected
tropical zoonoses. Such diseases often do not attract the interest of
health researchers or sufficient resources for adequate control, yet
they continue to impact significantly on human health and
wellbeing, livestock productivity and local and national economies.
There is a need for more accurate data relating to the burden of
neglected zoonoses to facilitate more effective implementation of
disease control interventions. In 2009, the Foodborne Disease
Burden Epidemiology Reference Group (FERG) of the World
Health Organization (WHO) commissioned a series of systematic
reviews on the burden of neglected zoonotic diseases, with the aim
of incorporating the findings into the overall global burden of
disease assessments.
This report presents a systematic review of scientific literature
published between 1990–June 2010 relating to the frequency of
human brucellosis. The objectives of this review were to identify
high quality disease incidence data to complement existing
knowledge [6] of the global disease burden and, ultimately, to
contribute towards the calculation of a Disability-Adjusted Life
Years (DALY) estimate for brucellosis. A systematic review of
scientific literature investigating the clinical manifestations of
brucellosis is the subject of a companion paper.
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Methods
Searching
Thirty three databases were searched for relevant articles using
the search strings of both (brucellosis OR malta fever) and
(brucellosis OR malta fever OR brucella melitensis OR brucella
abortus) AND (symptom* OR sequelae* OR morbidity OR
mortality OR transmission mode OR foodborne), with a
publication limitation of 1990–30 June, 2010. The search term
was adapted to the predominate language of the database. If a
database did not allow the combining of Boolean operators, (18 of
33 databases), ‘brucellosis’ was used as the sole term.
Reference Manager bibliographic software was used to manage
citations. Duplicate entries were identified by considering the
author, the year of publication, the title of the article, and the
volume, issue and page numbers of the source. In questionable
cases, the abstract texts were compared.
Selection
The articles were sorted by a team of four reviewers with a
combined fluency in English, German, French, and Spanish.
Articles in other languages were noted for future translation,
pending resources.
All reports were classified into one of two categories, based on
the abstracts:
Category 1: Relevant - articles related to human brucellosis
infection in populations (i.e. disease frequency) or cases of human
brucellosis (i.e. disease morbidity);
Category 2: Irrelevant - articles related to non-human
brucellosis; articles addressing topics not related to the current
review, such as genetics, laboratory diagnostic tests, experimental
laboratory animal studies
The abstracts of studies belonging to Category 1 and meeting
the following criteria for disease frequency were retained:
published between 1990 and 30 June 2010, at least 100 study
subjects drawn from the general population, prevalence or
incidence data included and some information relating to
diagnostic tests provided. The abstracts of studies meeting the
following criteria for disease morbidity were also retained:
published between 1990 and 30 June 2010, at least 10 study
subjects, clinical symptoms/syndromes described and some
information relating to diagnostic tests provided. The assessment
and classification of morbidity articles will be the subject of a
companion paper and will not be considered further here.
Articles for which the necessary data for classification could not
be obtained were identified for possible future assessment,
according to availability of resources. In general, non peer-
reviewed or review articles, conference proceedings and book
chapters were excluded.
Validity Assessment
After applying the aforementioned screening steps, the full text
of each selected article was retrieved for detailed analysis. Each
article was reviewed by two or three reviewers, and classification
discrepancies were resolved by discussion.
Frequency studies were classified as prevalence studies if they
stated a specified study population and area and an outcome
expressed as the proportion of the study population identified as
brucellosis seropositive (%); or as incidence studies if they presented
the time period of observation, information about the study
population size and area, and an outcome expressed as the number
of new brucellosis cases per population at risk per time period.
Articles were coded based on the following parameters:
1) Study design.
– Longitudinal - clear start/end date with a study period of
several months to years
– Cross-sectional - a short study period of several weeks or,
occasionally, several months
– Routine data – data officially reported by health services or
routine data recorded by a health facility or local authority
2) Sampling methods. The sampling approaches were
defined in order of decreasing quality as: cluster sampling
proportional to size, simple random cluster sampling, simple
random sampling without clustering or non-random sam-
pling. The method of case acquisition (active, passive) was
also evaluated. Studies not meeting any of these classifica-
tions were coded as ‘‘other’’.
3) Study level. The study area was categorised in decreasing
order of quality as: national, provincial, district or sub-
district level. Studies not meeting any of these classifications
were coded as ‘‘other’’.
4) Diagnostic methods. Tests were categorised in decreas-
ing order of quality as:
1. ELISA +/2 Rose Bengal Test (RBT) or lateral flow assay
only
2. RBT only
3. One of the following tests: microscopic agglutination test
(MAT), complement fixation test (CFT), 2-Mercaptoethy-
lamine test (2ME), standard tube agglutination test (STAT)
of 1:160 or greater dilution, Wright agglutination test
(WAT) or Huddleson test.
Studies diagnosing seropositives based on a STAT result of
a dilution of less than 1:160 were excluded.
Author Summary
Brucellosis is a bacterial disease transmitted to humans by
consumption of infected, unpasteurised animal milk or
through direct contact with infected animals, particularly
aborted foetuses. The livestock production losses resulting
from these abortions have a major economic impact on
individuals and communities. Infected people often suffer
from a chronic, debilitating illness. This systematic review
of the incidence of human brucellosis is the first ever
conducted. Using strict exclusion criteria, 28 scientific
articles published between January 1990–June 2010 which
included high quality data were identified. Half of these
studies presented incidence data and half presented
seroprevalence data which were converted to incidence
rates. Data were only available from 15 countries in the
regions of Northern Africa and Middle East, Western
Europe, Central and South America, Sub-Saharan Africa
and Central Asia. Brucellosis incidence varied widely
between and within countries. Demographic, occupational
and socioeconomic factors may play a role in these
differences. In many brucellosis-endemic countries, health
systems are weak, and official data are likely to underes-
timate the true disease burden. High quality research is
needed, particularly from Eastern Europe, the Asia-Pacific,
Central and South America and Africa. An integrated
approach to disease surveillance involving both human
health and veterinary services would allow a better
understanding of the disease, as well as a more cost-
effective utilisation of resources.
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5) Study quality. Studies were given an overall quality grade
of 1, 2, or 3, as shown in Table 1. Quality 1 studies had well
described study design and methods. Their sampling
approaches and study level were highly ranked, e.g. active
sampling by cluster sampling proportional to size or simple
random cluster sampling approaches at the national or
provincial level. The diagnostic methods were also highly
ranked, such as ELISA, lateral flow assay or RBT. Quality 2
studies contained some weaknesses in their sampling
approach and/or diagnostic methods. Although data were
extracted from Quality 3 studies, they were not included in
the final analysis, due to either a lack of information about
the methods and approaches preventing adequate assess-
ment of the quality of the study or obvious biases in study
design and implementation.
Data Extraction
The following information was extracted from each article, and
they were grouped according to geographic region, as identified by
the GBD consortium:
Seroprevalence studies: study period, size of study population,
seroprevalence as a percentage
Incidence studies: study period, size of reference population,
number of cases, incidence rate
Data Analysis
Seroprevalence data were multiplied by the duration of
seropositivity, assumed to be 10.9 years [7], to determine the
proportion of the general population seroconverting each year due
to brucellosis exposure. Using a conservative estimate of 10% of
seroconversions representing true clinical cases, these proportions
were multiplied by 0.1 and converted to rates per 100,000 person-
years for the general population.
Additional Targeted Searching
Given that high quality data were also likely to be available
through routine reporting systems in developed countries with
strong public health systems, additional data sources were
identified through a non-systematic, targeted search.
Results
Searching
Table 2 lists the databases searched and the number of articles
identified for each. A total of 28,824 articles were identified, of
which 59% were duplicates, leaving 11,000 original reports.
Flow of Selected Studies
Figure 1 shows a detailed flow diagram of the selection of articles
included in the systematic review. In total, 275 frequency and
morbidity studies were selected, for which full text was available for
153. However, 14 of these were in languages in which the team was
not competent (Croatian (6), Turkish (4), Korean (2), Persian (1),
Mandarin(1)), leaving 61 frequency studies for quality assessment.
Three were classified as Quality 1 and 26 as Quality 2. Thirty-two
were excluded from further analysis as Quality 3, due to either a
strong possibility of bias, a study population not representative of the
general population, or a lack of adequate information to allow a
proper assessment of study quality. Except for two articles in
Spanish, all Quality 1 and Quality 2 studies were in English.
Study Characteristics
Fifteen articles presented incidence data. Six of these were
longitudinal prospective studies [8–13], with the remainder
Table 1. Grading of study quality based on study methodology criteria.
Methodological Criteria Overall Study Quality
Quality 1 Quality 2 Quality 3
Sampling approach
Cluster sampling proportional to size 3 3
Simple random cluster sampling 3 3 3
Simple random sampling without clustering 3 3
Non-random sampling 3
Case acquisition
Active 3 3
Passive 3
Study level
National 3 3
Provincial 3 3 3
District 3 3 3
Sub-district 3 3
Diagnostic methods
ELISA with/without additional method 3 3
Lateral flow assay with/without additional method 3 3
RBT with additional method 3 3 3
RBT only 3 3
MAT, CFT, STAT, WAT, 2ME, Huddleson alone or in combination 3 3
doi:10.1371/journal.pntd.0001865.t001
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retrospectively reviewing data collected mainly in health centres
[14–21]. Three incidence studies did not describe the diagnostic
tests used but were included because they filled gaps in available
data and had otherwise well-documented methods and results
[15,17,20]. Seroprevalence data were presented in fourteen
articles, from surveys conducted in communities [22–28] or from
blood donor screening [29–32]. Due to a lack of data, several
studies focusing on specific sub-groups of the general population
where also included: two studies of nomadic communities [33,34]
and one of school children [35].
Studies of Quality 1 and 2 were only available for 15 countries
from the following GBD geographic regions: Northern African and
Middle East (17 studies) [8–11,14,16,18,19,22,25–27,30,32,34–36],
Western Europe (8 studies) [12,13,17,20,21,23,24,28], South and
Central America (2 studies) [29,31], Sub-Saharan Africa (1 study)
[33] and North America (1 study) [15], as shown in Figure 2. One
additional Quality 1 seroprevalence study from Central Asia [7] was
identified through targeted non-systematic searching which,
although not fulfilling the publication date criteria of the systematic
review, was included in data analysis because it provided otherwise
missing data.
Study characteristics of Quality 1 and 2 seroprevalence and
incidence articles are provided as Supplementary Information
(Tables S1 and S2), grouped byGBD geographic region. Confidence
intervals for seroprevalence estimates were only provided in four
articles [7,22,25,33]. The normal approximation to the binomial was
Table 2. Databases searched and number of hits.
Database Website No. hits
Global databases
Medline http://www.ncbi.nlm.nih.gov/sites/pubmed 6176
ISI Web of Science http://isiwebofknowledge.com 3458
EMBASE http://www.embase.com 4980
Popline http://www.popline.org 55
CAB http://www.cabdirect.org 3424
ProMed http://www.promedmail.org 666
The Cochrane Library http://www.thecochranelibrary.com 100
BIOLINE http://www.bioline.org.br 37
WHOLIS http://www.bireme.br 76
Regional WHO databases
African Index Medicus http://indexmedicus.afro.who.int 14
Index Medicus for the Eastern Mediterranean Region http://www.emro.who.int/whalecom0/Library/Databases
/wxis.exe/Library/Databases/iah/
526
Western Pacific Region Index Medicus http://www.wprim.org/ 96
Index Medicus for the South-East Asia Region http://imsear.hellis.org/ 247
Afro Library http://afrolib.afro.who.int/ 2
Other regional databases
Health Information Locator http://www.bireme.br 7
Institute of Tropical Medicine, Antwerp, Belgium http://lib.itg.be:8000/webspirs/start.ws 122
King’s Fund Information & Library Service http://www.kingsfund.org.uk/library/ 0
African Journals Online http://ajol.info/ 71
LILACS http://www.bireme.br 538
MedCarib http://www.bireme.br 9
REPIDISCA http://www.bireme.br 29
PAHO http://www.bireme.br 157
IBECS http://www.bireme.br 148
CUIDEN http://www.index-f.com/ 17
Indian Medlars Center IndMed http://indmed.nic.in/ 84
KoreaMed http://www.koreamed.org/SearchBasic.php 89
Japan Science and Technology Information Aggregator http://www.jstage.jst.go.jp/search/?typej = on&typep = on&typer = on&search = 1 137
Health Research and Development Information Network http://www.herdin.ph/ 0
Panteleimon http://www.panteleimon.org/maine.php3 6
l’Ecole Nationale de la Sante´ Publique http://test.bdsp.ehesp.fr/Base/ 191
La Bibliota`gue de Sante´ Tropicale http://www.santetropicale.com/resume/catalogue.asp 0
System for Information on Grey Literature in Europe http://opensigle.inist.fr 474
Swiss Tropical and Public Health Institute, Human and Animal
Health Unit, electronic departmental reference library
6906
doi:10.1371/journal.pntd.0001865.t002
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used to calculate confidence intervals for the prevalence estimates of
the remaining articles. Although some studies used a cluster-based
sampling approach, they did not present adequate information for
the calculation of adjusted confidence intervals.
Data Analysis
Table 3 shows the incidence of brucellosis in the general
population per 100,000 person-years by country, including rates
directly reported as well as those calculated from seroprevalences.
The studies are classified as containing data from the national
and/or sub-national level. Where incidence rates were reported
for several years, only the most recent data are provided.
A wide variation in reported brucellosis incidence is evident
regionally, as well as within countries. In the North Africa and
Middle East region, for example, incidences calculated from a
seroprevalence study in Iraq ranged from 52.3 cases per 100,000
Figure 1. Flow of selected studies. *Some frequency studies were also classified as morbidity studies.
doi:10.1371/journal.pntd.0001865.g001
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person-years in a rural area to 268.8 cases per 100,000 person-
years in a semi-rural area [25]. In Egypt, two prospective
incidence studies incorporating a surveillance system for acute
febrile illness in different rural areas provided rates of 18 [8] and
70 [9] cases per 1000,000 person-years. Only 5.7% of these cases
were detected through passive hospital-based surveillance [9].
Incidence rates in Western Europe and North America were
generally much lower than in other regions, although some within-
country variation was still evident. In Greece, for example,
respective rates of 4 [20] and 32 cases [13] per 100,000 person-
years were reported in western and central areas. The study in
western Greece also identified that one quarter of these cases,
although diagnosed in health facilities, were not officially reported
to the provincial public health department. Although rates in the
USA were very low, counties within 100 km of the Mexican
border had a higher disease incidence (0.18 compared to 0.02)
than those in non-border states [15].
Additional Targeted Searching
Surveillance data from the European Food Safety Authority
were obtained, giving an overall incidence for the European
Union of 0.08 cases per 100,000 person-years, three quarters of
which were reported by Greece, Spain, and Portugal [37]. Global
data obtained non-systematically from various sources including
health ministries, international organisations and scientific articles
has been previously summarised according to continent and
country by Pappas, and a global map was produced [6].
Discussion
The epidemiology of human brucellosis evolved over the
previous 15 years, as a result of socioeconomic factors, improved
surveillance systems, animal-based control programs and interna-
tional tourism [6]. Additionally, political changes have influenced
disease epidemiology, with brucellosis emerging as a major human
health problem in countries of the former Soviet Union following
its dissolution in 1991 [3].
The current review complements previous assessments of
brucellosis disease burden [6] by presenting epidemiological data
Figure 2. Geographical distribution of selected studies.
doi:10.1371/journal.pntd.0001865.g002
Table 3. Brucellosis incidence by country (cases per 100,000
person-years).
Country Study level
Incidence per
100,000 per year
North Africa and
Middle East
Egypt Sub-national 0.28–70.00
Iraq Sub-national 52.29–268.81
Iran Sub-national# 0.73–141.60
Jordan National 25.70–130.00
Oman Sub-national* 11.01
Palestine Sub-national 8.00
Saudi Arabia National 137.61
Sub-national 6.00–149.54
Turkey Sub-national 11.93–49.54
Sub-Saharan Africa
Chad Sub-national+ 34.86
Western Europe
Germany National 0.03
Greece Sub-national 4.00–32.49
Italy National 1.40
Central Asia
Kyrgyzstan National 88.00
Central and Southern
Latin America
Argentina Sub-national 12.84
Mexico Sub-national 25.69
North America
USA Sub-national 0.02–0.09
#includes one study of a nomadic community.
*children only.
+nomadic community.
doi:10.1371/journal.pntd.0001865.t003
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from scientific studies published between 1990–June 2010 which
have been quality screened according to strict criteria. There is an
obvious lack of high quality scientific data relating to brucellosis
incidence globally, with the majority of data coming from the
North Africa and Middle East region. Major gaps exist for Eastern
Europe and the Asia-Pacific, both of which had no available data,
as well as for Central and South America (only two studies) and
Africa (excluding Egypt, only one study). One of the major factors
limiting the usefulness of the identified studies was the lack of
clearly described methods, particularly in relation to sampling
approaches and case definitions. For many studies, it was not
possible to assess whether the study had been conducted in such a
way to minimise the risk of bias, resulting in the exclusion of data
that may have been of acceptable quality.
Brucellosis incidence varies widely not only between countries
but also within countries. Although it is not possible to rule out
study biases as potential causes of these differences, rates differing
by five times in one study in Iraq [25] or by four times in similarly
designed studies in Egypt [8,9] suggest that demographic,
occupational, and socioeconomic factors may play a role.
Aggregated data at national or regional levels cannot capture
these complexities of disease dynamics and, consequently, at-risk
populations or areas may be overlooked.
A lower disease incidence is seen in developed countries when
compared to low and middle income countries. However, brucellosis
still targets specific sub-groups of these populations, such as Turkish
immigrants in Germany [21] or Hispanic communities of low
socioeconomic status in the USA [15]. Brucellosis clearly remains a
disease of public health importance even in developed countries.
Although grey literature can provide high quality data, data
from well designed scientific studies are preferred. Passively
acquired national data in many brucellosis-endemic countries
are likely to underestimate the true disease burden. In an Egyptian
study incorporating an active acute febrile illness surveillance
system to identify and confirm suspected cases, brucellosis
incidence in the study area was 70 cases per 100,000 person-
years. Only 5.7% of these cases were identified through hospital-
based surveillance, from which the incidence rate would be
calculated as 3.8 cases per 100,000 person-years using a case
definition based on laboratory confirmation or 6 cases per 100,000
person-years using a clinical definition. Reliance on routine
hospital-based incidence data would have, therefore, underesti-
mated incidence by 12–18 times [9]. Official data from the
Ministry of Health provided an incidence rate of only 0.3 cases per
100,000 person-years [6].
Such underestimations of disease incidence could relate to
barriers to accessing health care or to case mismanagement and
misdiagnosis. A retrospective review of hospital records in western
Greece identified an additional source of error in official passively
acquired data, with a brucellosis under-reporting rate from
hospitals to the public health department of 26% [20]. Conse-
quently, one quarter of cases diagnosed through the hospital
system were not included in the official government data. Indeed,
incidence rates identified in studies conducted between 1999–2005
in different regions of Greece ranged from 4–32.5 cases per
100,000 person-years, whereas aggregated data published by the
European Food Safety provided a national incidence of just 0.9
cases per 100,000 person-years in 2009 [37].
Research Agenda
Strengthening public health systems would improve the quality
of data captured through routine reporting. In many brucellosis
endemic countries, however, health systems are weak and high
quality research is needed. Brucellosis incidence and prevalence
studies are notably lacking from Eastern Europe, the Asia-Pacific,
Central and South America and Sub-Saharan Africa. Researchers
must have an adequate foundation in the principles of epidemi-
ology and biostatistics to ensure that their studies are designed,
implemented, and analysed in a manner which minimises bias and
maximises the usefulness of the data.
Table 4. Key considerations for representative brucellosis seroprevalence and incidence studies.
Seroprevalence Incidence
Study population
Defined study zone, geographically or in terms of an administrative unit 3 3
Clear inclusion and exclusion criteria 3 3
Study population representative of general population, not high risk groups alone 3 3
Ongoing community education campaigns to raise disease awareness 3 3
Sampling
Sample size based on appropriate calculation, ideally including clustering of individuals 3
Random sampling strategy, ideally using probability proportional to size 3
Active surveillance system in health centres and/or in communities at household level 3
Multidisciplinary study team to investigate disease dynamics at animal-human interface 3 3
Diagnostic testing
Clearly described testing methods, including details of manufacturer or developer 3 3
Concise serological and clinical case definitions 3 3
ELISA, lateral flow or RBT preferred testing methods 3 3
Reporting
STROBE checklist followed [40] 3 3
Consideration of test performance in the analysis of results 3 3
Consideration of sensitivity of the surveillance system in the analysis of results 3
doi:10.1371/journal.pntd.0001865.t004
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An integrated approach to disease surveillance involving both
human health and veterinary services would allow a better
understanding of disease dynamics at the animal-human interface,
as well as a more cost-effective utilisation of resources [38,39]. A
checklist of requirements for representative seroprevalence and
incidence studies is given in Table 4.
Limitations
Although test performance was considered in the initial ranking
of each article and, thus, influenced study inclusion in the review,
the individual results of each study were not adjusted for test
performance. This is because test performance can vary signifi-
cantly according to test manufacturer or laboratory protocol, and
such detailed information was not available.
The calculation of incidence rates from seroprevalence studies is
based on two assumptions. The assumed duration of seropositivity
of 10.9 years has been determined mathematically using Vensim
software [7]. The assumption that 10% seroconversions represent
true clinical cases is conservative and is likely to underestimate the
true burden of disease.
Studies for which a title or abstract was not published in a
language using the Latin alphabet, such as those published only in
Chinese characters or Arabic script, may not have been identified
during the original database search. Of the foreign language
studies that were identified, those published in languages in which
the team was not competent were excluded from the analysis. It is
possible that some of these studies contained data that could have
contributed to this global assessment of brucellosis frequency.
Additionally, although studies in English were independently
reviewed by three team members, this was not always possible for
studies reviewed in other languages (German, French, Spanish).
Conclusion
This systematic review adds to the understanding of the global
burden of brucellosis by identifying high quality data from
scientific studies according to strict screening criteria. Disease
incidence varied significantly within regions and within countries.
Aggregated data do not capture the complexities of disease
dynamics and at-risk populations may be overlooked. As many
brucellosis-endemic countries do not have strong health systems,
passively acquired official data likely underestimate the true
burden. The brucellosis research agenda should focus on designing
and implementing high quality studies to investigate disease
seroprevalence and/or incidence, particularly in Eastern Europe,
the Asia-Pacific, Central and South America and Africa.
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